Dichloralphenazone

Identification

Name
Dichloralphenazone
Accession Number
DB01495
Type
Small Molecule
Groups
Approved, Illicit
Description

Dichloralphenazone is a US Schedule IV drug. It is a 1:2 mixture of Antipyrine with Chloral hydrate.

Structure
Thumb
Synonyms
Not Available
Active Moieties
NameKindUNIICASInChI Key
AntipyrineunknownT3CHA1B51H60-80-0VEQOALNAAJBPNY-UHFFFAOYSA-N
Chloral hydrateunknown418M5916WG302-17-0RNFNDJAIBTYOQL-UHFFFAOYSA-N
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Isometheptene Mucate, Dichloralphenazone, and AcetaminophenDichloralphenazone (100 mg/1) + Acetaminophen (325 mg/1) + Isometheptene mucate (65 mg/1)Capsule, gelatin coatedOralVilvet Pharmaceuticals Inc2011-05-012017-10-13Us
Isometheptene Mucate, Dichloralphenazone, and AcetaminophenDichloralphenazone (100 mg/1) + Acetaminophen (325 mg/1) + Isometheptene mucate (65 mg/1)CapsuleOralBurel Pharmaceuticals, Llc2016-04-162016-11-10Us
Isometheptene Mucate, Dichloralphenazone, and AcetaminophenDichloralphenazone (100 mg/1) + Acetaminophen (325 mg/1) + Isometheptene mucate (65 mg/1)CapsuleOralMacoven Pharmaceuticals2011-06-282017-12-20Us
Isometheptene Mucate/Dichloralphenazone/AcetaminophenDichloralphenazone (100 mg/1) + Acetaminophen (325 mg/1) + Isometheptene mucate (65 mg/1)CapsuleOralEci Pharmaceuticals Llc2011-02-152018-03-31Us
Isometheptene Mucate/Dichloralphenazone/AcetaminophenDichloralphenazone (100 mg/1) + Acetaminophen (325 mg/1) + Isometheptene mucate (65 mg/1)CapsuleOralPhysicians Total Care, Inc.2007-12-042012-06-30Us
Isometheptene-Dichloral-APAP OralDichloralphenazone (100 mg/1) + Acetaminophen (325 mg/1) + Isometheptene mucate (65 mg/1)CapsuleOralAv Kare, Inc.2015-05-202017-11-01Us
Isometheptene-Dichloral-APAP OralDichloralphenazone (100 mg/1) + Acetaminophen (325 mg/1) + Isometheptene mucate (65 mg/1)CapsuleOralMethod Pharmaceuticals2014-09-042017-11-20Us
LarkaDrinDichloralphenazone (100 mg/1) + Acetaminophen (325 mg/1) + Isometheptene mucate (65 mg/1)CapsuleOralLarken Laboratories, Inc.2012-07-172013-02-26Us
NodolorDichloralphenazone (100 mg/1) + Acetaminophen (325 mg/1) + Isometheptene mucate (65 mg/1)CapsuleOralMacoven Pharmaceuticals2011-06-282017-12-20Us
Categories
UNII
YYX637R279
CAS number
480-30-8
Weight
Average: 519.032
Monoisotopic: 515.934687938
Chemical Formula
C15H18Cl6N2O5
InChI Key
ATKXDQOHNICLQW-UHFFFAOYSA-N
InChI
InChI=1S/C11H12N2O.2C2H3Cl3O2/c1-9-8-11(14)13(12(9)2)10-6-4-3-5-7-10;2*3-2(4,5)1(6)7/h3-8H,1-2H3;2*1,6-7H
IUPAC Name
1,5-dimethyl-2-phenyl-2,3-dihydro-1H-pyrazol-3-one; bis(2,2,2-trichloroethane-1,1-diol)
SMILES
OC(O)C(Cl)(Cl)Cl.OC(O)C(Cl)(Cl)Cl.CN1N(C(=O)C=C1C)C1=CC=CC=C1

Pharmacology

Indication
Not Available
Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when Dichloralphenazone is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when Dichloralphenazone is combined with 3,4-Methylenedioxyamphetamine.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Dichloralphenazone.
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Dichloralphenazone.
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Dichloralphenazone is combined with 5-methoxy-N,N-dimethyltryptamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Dichloralphenazone is combined with 7-Nitroindazole.
AcepromazineThe risk or severity of adverse effects can be increased when Dichloralphenazone is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Dichloralphenazone is combined with Aceprometazine.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Dichloralphenazone.
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Dichloralphenazone.
Food Interactions
  • Avoid alcohol.

References

General References
  1. Hindmarch I, Parrott AC: The effects of combined sedative and anxiolytic preparations on subjective aspects of sleep and objective measures of arousal and performance the morning following nocturnal medication. I: Acute doses. Arzneimittelforschung. 1980;30(6):1025-8. [PubMed:6106498]
External Links
PubChem Compound
10188
PubChem Substance
46507898
ChemSpider
9776
ChEMBL
CHEMBL1697834
Wikipedia
Dichloralphenazone
ATC Codes
N05CC04 — Dichloralphenazone

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Capsule, gelatin coatedOral
CapsuleOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)68 °CPhysProp
Predicted Properties
PropertyValueSource
logP1.22ChemAxon
pKa (Strongest Basic)0.37ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area23.55 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity56.42 m3·mol-1ChemAxon
Polarizability20.41 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.991
Blood Brain Barrier+0.5901
Caco-2 permeable-0.5539
P-glycoprotein substrateNon-substrate0.8633
P-glycoprotein inhibitor INon-inhibitor0.9763
P-glycoprotein inhibitor IINon-inhibitor0.9465
Renal organic cation transporterNon-inhibitor0.9512
CYP450 2C9 substrateNon-substrate0.6054
CYP450 2D6 substrateNon-substrate0.8553
CYP450 3A4 substrateSubstrate0.5661
CYP450 1A2 substrateNon-inhibitor0.6408
CYP450 2C9 inhibitorNon-inhibitor0.8334
CYP450 2D6 inhibitorNon-inhibitor0.9366
CYP450 2C19 inhibitorNon-inhibitor0.7525
CYP450 3A4 inhibitorNon-inhibitor0.9689
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9289
Ames testNon AMES toxic0.7272
CarcinogenicityNon-carcinogens0.8129
BiodegradationNot ready biodegradable0.9958
Rat acute toxicity2.3391 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9976
hERG inhibition (predictor II)Non-inhibitor0.8907
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as chlorohydrins. These are alcohols substituted by a chlorine atom at a saturated carbon atom otherwise bearing only hydrogen or hydrocarbyl groups.
Kingdom
Organic compounds
Super Class
Organohalogen compounds
Class
Halohydrins
Sub Class
Chlorohydrins
Direct Parent
Chlorohydrins
Alternative Parents
Carbonyl hydrates / Organochlorides / Hydrocarbon derivatives / Alkyl chlorides
Substituents
Chlorohydrin / Carbonyl hydrate / Organic oxygen compound / Hydrocarbon derivative / Organooxygen compound / Organochloride / Alkyl halide / Alkyl chloride / Aromatic heteromonocyclic compound
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on July 31, 2007 07:09 / Updated on November 02, 2018 05:02